Newamsterdam Pharma Company N V Net Income per Employee (NAMS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Newamsterdam Pharma Company N v   (NASDAQ: NAMS)
 

Newamsterdam Pharma N V Net Income per Employee

NAMS's Quarterly Results, Trends, Rankings, Statistics
Newamsterdam Pharma Company N V recorded a cumulative net loss of $-213 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 353 other companies achieving higher income per employee. While Newamsterdam Pharma N V 's total ranking has deteriorated compared to the previous quarter from 2485 to 4009.


What is Income per Employee Ratio?






NAMS Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,127,330 -2,038,190 -2,377,200 -1,657,150 -1,873,580
NAMS's Total Ranking # 4009 # 2485 # 3499 # 0 # 0
Seq. Net Income Change - - - - -


NAMS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 354
Healthcare Sector # 792
Overall Market # 4009

Net Income per Employee Statistics
High Average Low
$ -2,038,190 $ -2,180,907 $ -2,377,200
(Dec 31 2025)   (Sep 30 2025)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-07-07T12:17:48+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.